You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Oxford Nanopore said it is rolling out the LamPore test globally, initially in the UK, Germany, Switzerland, and the United Arab Emirates.
Seasun Biomaterials' test is designed to detect SARS-CoV-2 RNA, while Zeus Scientific's test detects IgG antibodies against the virus.
The test uses real-time reverse transcription loop-mediated isothermal amplification to detect the SARS-CoV-2 N gene, according to CellSafe.
Color Genomics' kit is designed for the unmonitored self-collection of nasal swab specimens for SARS-CoV-2 testing.
The tests are designed to detect viral RNA in individual respiratory specimens, while BayCare's tests can be used with pooled samples.
In PNAS this week: genetic diversity of SARS-CoV-2 indicates neutral evolution, portable RT-LAMP method to detect SARS-CoV-2, and more.
Grassroots efforts are leading the way in a number of commercial and non-commercial screening tests in development.
The point-of-care test is based on technology developed at the Columbia University Fertility Center for preimplantation genetic testing.
Wired reports on an effort to use a loop-mediated isothermal amplification-based, or LAMP, test to screen for COVID-19 in a Wisconsin city.
A UK town is studying whether it can test its residents for COVID-19 each week, according to New Scientist.
Kaiser Health News reports San Francisco and Alameda counties in California are no longer using Verily Life Sciences' COVID-19 testing program.
The New York Times reports that developers in New York City are increasingly interested in life science spaces.
A UK study has found that antibodies against SARS-CoV-2 may decline over time, Reuters reports.
In PNAS this week: genetic and epigenetic variation in individuals with diabetic kidney disease, spontaneous genetic alterations in Saccharomyces cerevisiae, and more.
